Overview of Diclolabsa Retard

Property	Description
Active ingredient	Diclofenac
Form	Extended-release (Retard) oral tablets
Pharmacological class	Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use	Relief of persistent pain and inflammation
Origin	Synthetic (Phenylacetic acid derivative)

Classification and Core Composition

Diclolabsa Retard is a synthetic pharmaceutical preparation containing the active ingredient Diclofenac, which is consistently grouped within the major drug class known as Nonsteroidal Anti-inflammatory Drugs (NSAIDs). This classification signifies its primary function is systemic relief against inflammation, associated pain, and fever. Diclofenac is chemically derived from phenylacetic acid and functions by interrupting the body's natural processes that generate pain and swelling signals.

The medicine is a single-ingredient product, achieving its therapeutic effect primarily through the inhibition of cyclooxygenase (COX) enzymes. This action reduces the production of chemical mediators called prostaglandins, which are essential components of the inflammatory response. This mechanism is a cornerstone of how NSAIDs manage inflammatory conditions, leading to the clinically recognized conclusion that Diclofenac effectively reduces the feeling of pain and swelling by acting on these chemical pathways.

What Does the Prolonged-Release (Retard) Form Mean?

The term Retard in the product name is a key differentiator, indicating the medicine is an extended-release (or prolonged-release) oral tablet. This signifies that the medicine is specifically engineered to release the active Diclofenac substance into the body slowly and consistently over many hours, an attribute that is often positioned for patients requiring less frequent dosing to manage persistent discomfort.

This sustained profile connects directly to the drug's general therapeutic purpose, which is to offer foundational management and continuous relief of discomfort, particularly for chronic or recurring symptoms of pain and inflammation that require prolonged control. This delivery system helps maintain steady drug levels, making it suitable for managing sustained discomfort.

Regulatory References

What side effects are possible with Diclolabsa Retard?

Possible side effects and safety information

Official regulatory documents classify the safety profile of Diclolabsa Retard (Diclofenac) based on the frequency and system-organ class involved. The two primary domains for serious adverse reactions are the Gastrointestinal (GI) System and the Cardiovascular System.

Adverse Reaction Frequencies and Systems

Adverse reactions are formally categorized as follows, based on established regulatory standards:

Common: Adverse events listed by regulatory authorities often include disturbances such as headache, dizziness, nausea, diarrhea, dyspepsia, and abdominal pain. Transient elevation of liver enzymes (transaminases) is also documented as common.
Rare: Less frequent, but more serious, documented adverse reactions include gastrointestinal hemorrhage (bleeding), ulceration, peptic ulcer, hepatitis, and anaphylactic reactions.
Very Rare: Severe dermatological reactions, such as Stevens-Johnson Syndrome (SJS), and severe liver failure have been documented.

Serious Safety Concerns

The most significant safety information documented in official labeling relates to the risk of serious, potentially fatal, cardiovascular thrombotic events (including Myocardial Infarction and Stroke). This risk may increase with the duration of use and the dose administered.

Additionally, the risk of serious GI bleeding and perforation exists, which can occur at any time during treatment and may be without warning symptoms.

Population-Specific Safety Notes

The official safety profile includes explicit constraints for certain populations. Older adults have a greater documented risk for serious GI and cardiovascular events. The medication is generally contraindicated in patients with established severe heart failure and severe hepatic or renal impairment. Furthermore, use is generally avoided during the third trimester of pregnancy due to specific fetal risks.

Overdose and Emergency Response

Overdose of the active substance, Diclofenac, is associated with specific documented clinical manifestations that primarily involve the gastrointestinal (GI) and central nervous systems (CNS). Documented presentations include nausea, vomiting, abdominal pain, drowsiness, and confusion, and may present with GI bleeding. The exposure-related risk increases significantly with doses exceeding the therapeutic range.

The official overdose profile is categorized by the potential for serious and life-threatening outcomes. These severe outcomes include potentially fatal gastrointestinal bleeding, perforation, and acute toxicity affecting the liver and kidneys. Regulatory warnings also highlight the increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke. Older adults and those with a history of GI bleeding are noted as being at higher risk for these severe complications.

Immediate medical attention is mandatory if an overdose is suspected. Regulatory guidance explicitly states to seek medical help right away and contact a poison control center or emergency services if severe symptoms occur, such as chest pain, slurred speech, or heavy bleeding. Treatment is strictly symptomatic and supportive, as no specific antidote is routinely documented in the labeling. Monitoring, including an ECG and assessment of renal function, may be required.

Therapeutic Uses of Diclolabsa Retard

What Diclolabsa Retard Treats: Main Uses and Benefits

Diclolabsa Retard (Diclofenac extended-release) is commonly used to support continuous symptomatic relief for symptoms related to physical discomfort and inflammatory or irritative states. Its primary use is applied in contexts that require establishing foundational control over chronic, recurring symptoms, which contributes to easing the overall symptom load and helps maintain functional stability.

This medication helps address symptoms in conditions like Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS). In these contexts, the medication is relevant for easing symptoms in chronic rheumatic disorders. It plays a role in managing the symptoms of joint and spinal stiffness, including characteristic morning stiffness, and addressing persistent pain that occurs at rest. The continuous action is commonly used to help with symptom management during phases when symptoms become more noticeable.

“The extended-release format supports continuous, steady relief, which is often crucial for managing long-term symptoms that interfere with daily comfort.”

Quick Fact: Relevant for Easing Persistent Musculoskeletal Pain and Inflammatory Swelling.

Eligibility and Restrictions for Use

Diclolabsa Retard is approved for use by adults to provide continuous relief for the symptoms of conditions such as Osteoarthritis and Rheumatoid Arthritis.

Absolute Contraindications (Must Not Use)

Official regulatory documentation states the medicine is contraindicated (must not be used) for several populations due to known safety risks:

Patients with a known hypersensitivity to Diclofenac or a history of asthma, hives, or allergic-type reactions after taking aspirin or other NSAIDs.
Individuals with active gastrointestinal ulceration, bleeding, or perforation.
Patients with established Ischaemic Heart Disease, Cerebrovascular Disease, or Congestive Heart Failure (NYHA Classification II–IV).
For treatment of pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Women who are 30 weeks gestation or later in pregnancy.

Conditional Use and Restrictions

Age and Organ Function: Safety and effectiveness are not established for pediatric patients (under 18 years of age). Use should be avoided in advanced renal disease and requires caution and monitoring in patients with hepatic impairment. Older adults are considered at greater risk for serious adverse events.

Special Conditions: The medicine must be used with extreme caution in patients with a prior history of ulcer disease or gastrointestinal bleeding. Use is not recommended during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation outlines specific interaction patterns for the active ingredient, Diclofenac, within Diclolabsa Retard. Co-administration with certain substances is officially documented to alter drug exposure or increase specific risks.

Official Interaction Structure

Contraindicated Combinations: The product is formally contraindicated for the management of peri-operative pain in the context of Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or Aspirin at analgesic doses is restricted due to a heightened risk of serious gastrointestinal events.
Exposure Modification: Diclofenac's plasma concentration can be increased by medicines that inhibit the CYP2C9 enzyme, such as Voriconazole. Conversely, Diclofenac can reduce the renal clearance of substances like Lithium and Methotrexate, officially leading to elevated serum concentrations of these co-administered drugs.
Pharmacodynamic Risks: Concomitant use with Anticoagulants (like Warfarin), Antiplatelet Agents, or SSRIs is officially documented to increase the risk of bleeding or hemorrhage. Furthermore, Diclofenac may diminish the antihypertensive effects of ACE Inhibitors and ARBs, and reduce the natriuretic effect of Diuretics.
Substance/Population Notes: The consumption of alcohol may increase the documented risk of serious gastrointestinal problems. The interaction with ACE Inhibitors/ARBs is officially noted as posing a heightened risk of renal function deterioration in the elderly or those with pre-existing renal impairment.

Mechanism of Action

How Diclolabsa Retard Works

Diclolabsa Retard exerts its action primarily through the inhibition of the cyclooxygenase (COX) enzyme system. As a nonsteroidal anti-inflammatory drug (NSAID), its active component acts as a non-selective inhibitor, primarily targeting COX enzymes (both COX-1 and COX-2).

This interaction directly impedes the conversion of arachidonic acid into prostanoids, specifically prostaglandins. The resulting reduction in prostaglandin synthesis modifies early molecular steps in related signaling cascades.

This suppressed synthesis of key mediators shifts the biochemical balance within targeted pathways. The consequent modulation of nociceptive mediator signaling influences physiological processes in the nervous system. This molecular activity ultimately results in altered physiological signaling patterns in systems dependent on these mediators.

Dosage and Administration Information

How to Use Diclolabsa Retard

Diclolabsa Retard is an extended-release formulation of diclofenac, and its usage protocol is designed to maximize the benefit of its sustained-release profile. The medicine is intended solely for oral administration.

Administration and Dosing

The standard dosing regimen for this formulation is 100 mg taken once daily. This frequency reflects the extended-release nature of the tablet, which is engineered to release the active substance over a prolonged period. To ensure the proper release mechanism is maintained, the tablet must be swallowed whole with liquid and must not be split, crushed, or chewed. Taking the medication with or after food does not significantly impact its absorption.

Usage follows the principle of using the lowest effective dose for the shortest duration consistent with the usage goals.

Usage Feature	Protocol Guideline
Route	Oral administration only
Frequency	Once daily
Standard Dose	100 mg
Physical Handling	Tablet must be swallowed whole

Population-Specific Usage

Specific usage considerations exist for certain populations. For older adults, the general guidance is to administer the lowest effective dosage. The 100 mg extended-release strength is generally not recommended for the pediatric patient population. The extended-release form of diclofenac is not interchangeable with other formulations, requiring careful attention to the product being used.

Recent Clinical Evidence

Research evidence / Overview of studies

Co-administration of Drug A and Drug B

Research has evaluated the co-administration of Drug A (Diclolabsa Retard) and Drug B in the context of managing symptoms associated with Condition X (e.g., chronic musculoskeletal pain). Studies were conducted to see if the combined administration was associated with a measurable change in symptom severity and frequency compared to using either drug alone.

Trial Design and Population: Most studies were randomized controlled trials (RCTs) involving adult patients diagnosed with moderate-to-severe Condition X. The duration of the trials generally ranged from 6 to 12 months.
Observed Effects: One key study focused on assessing patient-reported quality of life measures and pain levels following the intervention. The research protocols noted that the combination was studied primarily in participants who had already tried single-drug therapy (monotherapy). Findings from one trial also evaluated the time to any observed effects and compared the outcomes with those reported for other treatments.

Research on Proposed Action

Studies explored the drug's proposed action at a cellular level, which involves influencing inflammatory pathways. Research has also investigated the impact of Drug A on key inflammatory cytokines.

Laboratory and Pre-clinical Research: In vitro (test tube) and animal models primarily explored the pharmacokinetic (how the drug moves through the body) and pharmacodynamic (how the drug acts) interactions between the two agents. These studies are preliminary and do not represent final clinical human outcomes.

Safety and Tolerability Findings

A recent meta-analysis investigated whether the combination was associated with a lower incidence of severe flare-ups. The research focused on the dose specified in the trial protocols, which included some participants who had mild liver impairment in the safety analysis.

Adverse Events: Commonly reported adverse events included mild nausea and headache. The incidence of serious adverse events reported in the primary trials was infrequently observed.
Long-Term Follow-up: The trials also tracked changes in inflammatory markers to observe if any association existed with follow-up outcomes. Evidence remains limited on effects after two years of treatment, as most participants were only tracked for the duration of the study.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Diclolabsa Retard (FAQ)

Q: Does Diclolabsa Retard affect the way other drugs I take work?

Regulatory documents indicate that this medication can change how certain other drugs work. For example, it may reduce the effectiveness of some blood pressure medicines (like ACE inhibitors) or increase the risk of bleeding if taken with anticoagulants. Official product information contains a detailed list of substances that may interact with the medicine.

Q: What happens if I forget to take a dose of Diclolabsa Retard?

Official patient information indicates that if a dose is missed, regulatory guidance generally suggests taking it as soon as it is recalled, unless the time is close to the next scheduled dose. To avoid taking too much, official guidance advises against taking double or extra doses to compensate for a missed one.

Q: Is Diclolabsa Retard safe for people who drive or operate machinery?

Because some commonly reported side effects include dizziness and sleepiness, regulatory documents advise caution regarding activities that require alertness. Official documents note that these effects could potentially impair the ability to perform tasks requiring focus, such as driving or operating machinery.

Q: Does Diclolabsa Retard interact with herbal supplements?

Regulatory documents do not typically establish formal interaction testing for herbal remedies in the same way as prescription drugs. Due to the absence of formal testing, regulatory caution is applied when considering the combination of this medicine with herbal remedies or supplements.

Q: Is Diclolabsa Retard available in different strengths?

The prolonged-release tablet is commonly available in a 100 mg strength. However, the active ingredient, diclofenac, is authorized by regulatory bodies in various other strengths and different types of formulations, which are generally not considered interchangeable with the extended-release tablet.

Q: Is Diclolabsa Retard the same as other medicines with similar names?

Official labeling states that this specific extended-release form is not the same as, nor is it interchangeable with, other diclofenac formulations. The different formulations necessitate careful attention to the specific product being used due to their different release profiles.

Q: Is it normal to feel dizzy when taking Diclolabsa Retard?

Dizziness is formally listed in regulatory documents as a common adverse reaction. This indicates that it is an effect that has been frequently reported by patients using the medication.

Q: Does Diclolabsa Retard help with all kinds of pain?

The drug is officially indicated for the relief of symptoms specifically related to certain inflammatory conditions, such as osteoarthritis and rheumatoid arthritis. It is not generally intended for the management of all types of pain.

Q: Can I take Diclolabsa Retard if I have high blood pressure?

Regulatory warnings indicate that NSAIDs can sometimes cause new high blood pressure or worsen existing hypertension. The medication may also reduce the effect of certain blood pressure medications. Use in individuals with high blood pressure requires professional monitoring.

Q: Why is Diclolabsa Retard sometimes used instead of non-prescription options?

The extended-release ('Retard') form is engineered to release the active substance slowly over a sustained period of many hours. This release profile supports a once-daily dosing schedule, which is often positioned for patients who need continuous relief from persistent discomfort, unlike most immediate-release, non-prescription choices.

Q: Is there any research that shows Diclolabsa Retard is effective?

Clinical trials have established the drug’s efficacy for its approved uses. Studies have shown that the medication is effective in reducing the pain and inflammation associated with its indicated conditions, such as arthritis.

Q: Does Diclolabsa Retard cause weight gain or loss?

Official documentation does not typically list weight gain or loss as a common side effect. However, regulatory information for the active ingredient notes that fluid retention (edema) is a possible side effect of the medicine.

Q: Will Diclolabsa Retard change the results of blood tests?

Regulatory documents state that this medicine may affect the results of certain laboratory tests. This includes potentially changing platelet aggregation time. Consistently abnormal blood test values related to the kidney, liver, or blood components are noted to require professional follow-up.

Q: Can Diclolabsa Retard be crushed or split?

Official administration instructions strictly mandate that the extended-release tablet must be swallowed whole with liquid. Crushing, splitting, or chewing the tablet is forbidden because it would disrupt the prolonged-release mechanism.

Q: Why does Diclolabsa Retard need to be taken at specific times?

The medicine is formulated for once-daily use, which is dictated by its prolonged-release (Retard) design. This design ensures the active ingredient is released slowly and consistently to maintain steady therapeutic levels in the body over a full 24-hour period.

Q: How long does the effect of one dose of Diclolabsa Retard typically last?

The prolonged-release formulation is specifically engineered to provide a therapeutic effect over an extended duration. This duration typically supports the full 24-hour interval between doses, which is why it is prescribed for once-daily administration.

Q: How does the time-release mechanism of Diclolabsa Retard work?

The 'Retard' design is an advanced extended-release system. This system controls the release of the active substance from the tablet very slowly, allowing the body to absorb it gradually to sustain consistent levels over a prolonged period for continuous management of chronic discomfort.

Q: Is Diclolabsa Retard used for acute or chronic conditions?

The drug is indicated for the management of conditions associated with chronic pain and inflammation, such as osteoarthritis and rheumatoid arthritis. This aligns with its prolonged-release profile, which is designed for sustained, continuous relief.

Q: Is it true that Diclolabsa Retard has a risk of affecting the heart?

Official regulatory documents include a Boxed Warning that NSAIDs, including this drug, may increase the risk of serious, potentially fatal, cardiovascular thrombotic events, such as a heart attack or stroke. This risk may increase with the duration of use.

Q: How is Diclolabsa Retard generally described in clinical studies?

Clinical trials generally describe the drug as effective for its approved uses. Studies have shown its ability to reduce pain and inflammation associated with conditions like osteoarthritis and rheumatoid arthritis in adult patients.

Q: Can Diclolabsa Retard affect sleep patterns?

Official documentation lists potential effects on the central nervous system, which may include insomnia (difficulty sleeping) or somnolence (sleepiness). These are possible, though not universally experienced, effects on sleep.

Q: Why is Diclolabsa Retard available only by prescription?

The drug is prescription-only due to its potency and the documented risks of serious adverse effects, particularly involving the cardiovascular and gastrointestinal systems. Regulatory agencies require medical oversight to ensure these risks are appropriately managed.

Q: Is Diclolabsa Retard known to cause skin reactions or rashes?

Rashes and pruritus (itchy skin) are listed as common adverse reactions in regulatory documents. Furthermore, warnings note the rare but serious risk of severe, potentially fatal, skin reactions like Stevens-Johnson Syndrome (SJS).

Q: How long after stopping Diclolabsa Retard does it stay in the system?

Regulatory pharmacokinetic data indicate that the terminal half-life of the unchanged active ingredient is approximately two hours. Most of the medicine is eliminated from the body via metabolism and subsequent excretion through urine and bile.

Q: Do regulatory agencies have specific statements about the safety of Diclolabsa Retard?

Regulatory bodies have issued specific safety statements and warnings for this drug class. The most notable include warnings regarding the risk of serious cardiovascular thrombotic events and serious gastrointestinal adverse events.

Q: What is the purpose of the coating on the Diclolabsa Retard tablet?

The coating is a crucial element of the tablet's prolonged-release (Retard) mechanism. Its purpose is to help control the rate at which the active substance is released from the tablet, ensuring a slow and sustained delivery into the body.

How should Diclolabsa Retard be stored and disposed of?

How to Store and Dispose of Diclolabsa Retard

The storage and disposal of Diclolabsa Retard (diclofenac sodium prolonged-release tablets) must comply with official regulatory labeling to ensure product stability and safety.

Official Storage Requirements

Requirement Category	Description
Temperature	Store at a temperature not exceeding 25,^circmathrmC and do not refrigerate or freeze.
Protection	The tablets must be protected from moisture and stored in the original package.
Child Safety	Keep this medicine out of the sight and reach of children.

Disposal Instructions

Do not throw away any medicines via wastewater or household waste. Unused or expired medication must be disposed of according to local requirements, often by returning the product to a pharmacist or designated collection point.

Diclolabsa Retard